Marchesini Group invests in serialisation software and 3D printing

By Dan Stanton contact

- Last updated on GMT

Part of the firm's expansion includes 3D printing, a new facility for which is set to open in Bologna, Italy. Image c/o Marchesini Group
Part of the firm's expansion includes 3D printing, a new facility for which is set to open in Bologna, Italy. Image c/o Marchesini Group

Related tags: Pharmacology

Pharma packaging firm Marchesini Group has acquired 48% of its serialisation software partner SEA Vision and forged a long-term agreement worth €125m.

The deal will see Italian packaging firm Marchesini Group own 48% of vision system software company SEA Vision, a firm they have partnered with on various projects in the past including for serialisation technology systems​.

“SEA Vision is really important for the Marchesini Group. In 35 years, this is the first M&A operation that involves not a mechanical firm but a softwarehouse,”​ Marchesini spokesperson Antonio Leggieri told in-Pharmatechnologist.

SEA Vision is a world point of reference for vision systems in the pharma industry,”​ and already their systems are present on 85% of the Marchesini machines, he said.

Leggieri did not reveal how much the company paid for the 48% share but said it is worth €125m ($156m) as a long-term strategic agreement between the two companies.

SEA Vision clocked in sales of €32m last year, but has predicted revenues to shoot up by 40% this year due to pharma serialization regulations across an increasing number of markets.

In the US, for example, a second-wave of track-and trace regulations came into effect last year​ and in Europe the Falsified Medicines Directive (EUFMD) makes serialisation of licensed drug products a legal requirement from early 2019.

3D printing

The Marchesini Group is also set to inaugurate a facility built entirely for 3D printing.

The 1,000m2​ factory, located within the firm’s headquartes in Pianoro, Bologna, represents an investment of between €5-6m and will be available to all customers.

“The parts printed are used for the customers’ machines,”​ said Leggieri. “The printers are also able to create prototypes, so the Group can develop them inside and not outside.”

Related news

Show more

Related products

show more

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Related suppliers

Follow us

Products

View more

Webinars